Notice (8): Undefined variable: solution_of_interest [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'product' => array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
[maximum depth reached]
),
'Master' => array(
[maximum depth reached]
),
'Product' => array(
[maximum depth reached]
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
)
),
'Category' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
)
),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
),
(int) 7 => array(
[maximum depth reached]
)
)
),
'meta_canonical' => 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
)
$language = 'en'
$meta_keywords = ''
$meta_description = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$meta_title = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$product = array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
'id' => '276',
'name' => 'C15310197',
'product_id' => '2135',
'modified' => '2020-05-12 11:15:05',
'created' => '2020-05-12 11:15:05'
),
'Master' => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
),
'Product' => array(
(int) 0 => array(
[maximum depth reached]
)
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
'id' => '19',
'position' => '10',
'parent_id' => '40',
'name' => 'WB',
'description' => '<p><strong>Western blot</strong> : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies.</p>
<p>Learn more about: <a href="https://www.diagenode.com/applications/western-blot">Loading control, MW marker visualization</a><em>. <br /></em></p>
<p><em></em>Check our selection of antibodies validated in Western blot.</p>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'western-blot-antibodies',
'meta_keywords' => ' Western Blot Antibodies ,western blot protocol,Western Blotting Products,Polyclonal antibodies ,monoclonal antibodies ',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for western blot applications',
'meta_title' => ' Western Blot - Monoclonal antibody - Polyclonal antibody | Diagenode',
'modified' => '2016-04-26 12:44:51',
'created' => '2015-01-07 09:20:00',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '20',
'position' => '10',
'parent_id' => '40',
'name' => 'ELISA',
'description' => '<div class="row">
<div class="small-12 medium-12 large-12 columns">Enzyme-linked immunosorbent assay.</div>
</div>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'elisa-antibodies',
'meta_keywords' => ' ELISA Antibodies,Monoclonal antibody, Polyclonal antibody',
'meta_description' => 'Diagenode offers Monoclonal & Polyclonal antibodies for ELISA applications',
'meta_title' => 'ELISA Antibodies - Monoclonal & Polyclonal antibody | Diagenode',
'modified' => '2016-01-13 12:21:41',
'created' => '2014-07-08 08:13:28',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '42',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-seq (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-seq-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP Sequencing applications',
'meta_title' => 'ChIP Sequencing Antibodies (ChIP-Seq) | Diagenode',
'modified' => '2016-01-20 11:06:19',
'created' => '2015-10-20 11:44:45',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
[maximum depth reached]
)
)
),
'Category' => array(
(int) 0 => array(
'id' => '17',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-seq grade antibodies',
'description' => '<p><b>Unparalleled ChIP-Seq results with the most rigorously validated antibodies</b></p>
<p><span style="font-weight: 400;">Diagenode provides leading solutions for epigenetic research. Because ChIP-seq is a widely-used technique, we validate our antibodies in ChIP and ChIP-seq experiments (in addition to conventional methods like Western blot, Dot blot, ELISA, and immunofluorescence) to provide the highest quality antibody. We standardize our validation and production to guarantee high product quality without technical bias. Diagenode guarantees ChIP-seq grade antibody performance under our suggested conditions.</span></p>
<div class="row">
<div class="small-12 medium-9 large-9 columns">
<p><strong>ChIP-seq profile</strong> of active (H3K4me3 and H3K36me3) and inactive (H3K27me3) marks using Diagenode antibodies.</p>
<img src="https://www.diagenode.com/img/categories/antibodies/chip-seq-grade-antibodies.png" /></div>
<div class="small-12 medium-3 large-3 columns">
<p><small> ChIP was performed on sheared chromatin from 100,000 K562 cells using iDeal ChIP-seq kit for Histones (cat. No. C01010051) with 1 µg of the Diagenode antibodies against H3K27me3 (cat. No. C15410195) and H3K4me3 (cat. No. C15410003), and 0.5 µg of the antibody against H3K36me3 (cat. No. C15410192). The IP'd DNA was subsequently analysed on an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 36 bp tags were aligned to the human genome using the ELAND algorithm. The figure shows the signal distribution along the complete sequence of human chromosome 3, a zoomin to a 10 Mb region and a further zoomin to a 1.5 Mb region. </small></p>
</div>
</div>
<p>Diagenode’s highly validated antibodies:</p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-seq-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-seq grade antibodies,polyclonal antibody,WB, ELISA, ChIP-seq (ab), ChIP-qPCR (ab)',
'meta_description' => 'Diagenode Offers Wide Range of Validated ChIP-Seq Grade Antibodies for Unparalleled ChIP-Seq Results',
'meta_title' => 'Chromatin Immunoprecipitation ChIP-Seq Grade Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:22',
'created' => '2015-02-16 02:24:01',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 1 => array(
'id' => '127',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-grade antibodies',
'description' => '<div class="row">
<div class="small-12 columns"><center></center>
<p><br />Chromatin immunoprecipitation (<b>ChIP</b>) is a technique to study the associations of proteins with the specific genomic regions in intact cells. One of the most important steps of this protocol is the immunoprecipitation of targeted protein using the antibody specifically recognizing it. The quality of antibodies used in ChIP is essential for the success of the experiment. Diagenode offers extensively validated ChIP-grade antibodies, confirmed for their specificity, and high level of performance in ChIP. Each batch is validated, and batch-specific data are available on the website.</p>
<p></p>
</div>
</div>
<p><strong>ChIP results</strong> obtained with the antibody directed against H3K4me3 (Cat. No. <a href="../p/h3k4me3-polyclonal-antibody-premium-50-ug-50-ul">C15410003</a>). </p>
<div class="row">
<div class="small-12 medium-6 large-6 columns"><img src="https://www.diagenode.com/img/product/antibodies/C15410003-fig1-ChIP.jpg" alt="" width="400" height="315" /> </div>
<div class="small-12 medium-6 large-6 columns">
<p></p>
<p></p>
<p></p>
</div>
</div>
<p></p>
<p>Our aim at Diagenode is to offer the largest collection of highly specific <strong>ChIP-grade antibodies</strong>. We add new antibodies monthly. Find your ChIP-grade antibody in the list below and check more information about tested applications, extensive validation data, and product information.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-grade antibodies, polyclonal antibody, monoclonal antibody, Diagenode',
'meta_description' => 'Diagenode Offers Extensively Validated ChIP-Grade Antibodies, Confirmed for their Specificity, and high level of Performance in Chromatin Immunoprecipitation ChIP',
'meta_title' => 'Chromatin immunoprecipitation ChIP-grade antibodies | Diagenode',
'modified' => '2024-11-19 17:27:07',
'created' => '2017-02-14 11:16:04',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 2 => array(
'id' => '102',
'position' => '1',
'parent_id' => '4',
'name' => 'Sample size antibodies',
'description' => '<h1><strong>Validated epigenetics antibodies</strong> – care for a sample?<br /> </h1>
<p>Diagenode has partnered with leading epigenetics experts and numerous epigenetics consortiums to bring to you a validated and comprehensive collection of epigenetic antibodies. As an expert in epigenetics, we are committed to offering highly-specific antibodies validated for ChIP/ChIP-seq and many other applications. All batch-specific validation data is available on our website.<br /><a href="../categories/antibodies">Read about our expertise in antibody production</a>.</p>
<ul>
<li><strong>Focused</strong> - Diagenode's selection of antibodies is exclusively dedicated for epigenetic research. <a title="See the full collection." href="../categories/all-antibodies">See the full collection.</a></li>
<li><strong>Strict quality standards</strong> with rigorous QC and validation</li>
<li><strong>Classified</strong> based on level of validation for flexibility of application</li>
</ul>
<p>Existing sample sizes are listed below. We will soon expand our collection. Are you looking for a sample size of another antibody? Just <a href="mailto:agnieszka.zelisko@diagenode.com?Subject=Sample%20Size%20Request" target="_top">Contact us</a>.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => true,
'is_antibody' => true,
'slug' => 'sample-size-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => '5-hmC monoclonal antibody,CRISPR/Cas9 polyclonal antibody ,H3K36me3 polyclonal antibody,diagenode',
'meta_description' => 'Diagenode offers sample volume on selected antibodies for researchers to test, validate and provide confidence and flexibility in choosing from our wide range of antibodies ',
'meta_title' => 'Sample-size Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:05',
'created' => '2015-10-27 12:13:34',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 3 => array(
'id' => '30',
'position' => '50',
'parent_id' => '4',
'name' => 'Transcription',
'description' => '<p><span style="font-weight: 400;">The list of Diagenode’s highly specific antibodies for transcription studies includes the antibodies against many transcription factors and nuclear receptors. Check the list below to see our targets.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li><span style="font-weight: 400;"> Highly sensitive and specific</span></li>
<li><span style="font-weight: 400;"> Cost-effective (requires less antibody per reaction)</span></li>
<li><span style="font-weight: 400;"> Batch-specific data is available on the website</span></li>
<li><span style="font-weight: 400;"> Expert technical support</span></li>
<li><span style="font-weight: 400;"> Sample sizes available</span></li>
<li><span style="font-weight: 400;"> 100% satisfaction guarantee</span></li>
</ul>',
'no_promo' => false,
'in_menu' => false,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'transcription-factor',
'cookies_tag_id' => null,
'meta_keywords' => ' Transcription factor antibodies,monoclonal antibodies,polyclonal antibodies',
'meta_description' => 'Diagenode offers polyclonal and monoclonal antibodies for Transcription studie',
'meta_title' => 'Transcription factor Antibodies | Diagenode',
'modified' => '2020-07-06 12:59:19',
'created' => '2015-03-12 10:20:08',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 4 => array(
'id' => '103',
'position' => '0',
'parent_id' => '4',
'name' => 'All antibodies',
'description' => '<p><span style="font-weight: 400;">All Diagenode’s antibodies are listed below. Please, use our Quick search field to find the antibody of interest by target name, application, purity.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'all-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'Antibodies,Premium Antibodies,Classic,Pioneer',
'meta_description' => 'Diagenode Offers Strict quality standards with Rigorous QC and validated Antibodies. Classified based on level of validation for flexibility of Application. Comprehensive selection of histone and non-histone Antibodies',
'meta_title' => 'Diagenode's selection of Antibodies is exclusively dedicated for Epigenetic Research | Diagenode',
'modified' => '2019-07-03 10:55:44',
'created' => '2015-11-02 14:49:22',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
)
),
'Document' => array(
(int) 0 => array(
'id' => '11',
'name' => 'Antibodies you can trust',
'description' => '<p style="text-align: justify;"><span>Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of large sets of genome-wide sequencing data. ChIP sequencing (ChIP-seq) has now become the gold standard method for chromatin studies, given the accuracy and coverage scale of the approach over other methods. Successful ChIP-seq, however, requires a higher level of experimental accuracy and consistency in all steps of ChIP than ever before. Particularly crucial is the quality of ChIP antibodies. </span></p>',
'image_id' => null,
'type' => 'Poster',
'url' => 'files/posters/Antibodies_you_can_trust_Poster.pdf',
'slug' => 'antibodies-you-can-trust-poster',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2015-10-01 20:18:31',
'created' => '2015-07-03 16:05:15',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '38',
'name' => 'Epigenetic Antibodies Brochure',
'description' => '<p>More than in any other immuoprecipitation assays, quality antibodies are critical tools in many epigenetics experiments. Since 10 years, Diagenode has developed the most stringent quality production available on the market for antibodies exclusively focused on epigenetic uses. All our antibodies have been qualified to work in epigenetic applications.</p>',
'image_id' => null,
'type' => 'Brochure',
'url' => 'files/brochures/Epigenetic_Antibodies_Brochure.pdf',
'slug' => 'epigenetic-antibodies-brochure',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2016-06-15 11:24:06',
'created' => '2015-07-03 16:05:27',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '1783',
'name' => 'product/antibodies/chipseq-grade-ab-icon.png',
'alt' => 'ChIP-seq Grade',
'modified' => '2020-11-27 07:04:40',
'created' => '2018-03-15 15:54:09',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '3778',
'name' => 'RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.',
'authors' => 'Ptasinska A, Pickin A, Assi SA, Chin PS, Ames L, Avellino R, Gröschel S, Delwel R, Cockerill PN, Osborne CS, Bonifer C',
'description' => '<p>Acute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maintenance of t(8;21) AML is dependent on RUNX1-ETO expression. Its depletion causes extensive changes in transcription factor binding, as well as gene expression, and initiates myeloid differentiation. However, how these processes are connected within a gene regulatory network is unclear. To address this question, we performed Promoter-Capture Hi-C assays, with or without RUNX1-ETO depletion and assigned interacting cis-regulatory elements to their respective genes. To construct a RUNX1-ETO-dependent gene regulatory network maintaining AML, we integrated cis-regulatory element interactions with gene expression and transcription factor binding data. This analysis shows that RUNX1-ETO participates in cis-regulatory element interactions. However, differential interactions following RUNX1-ETO depletion are driven by alterations in the binding of RUNX1-ETO-regulated transcription factors.</p>',
'date' => '2019-09-17',
'pmid' => 'http://www.pubmed.gov/31533028',
'doi' => '10.1016/j.celrep.2019.08.040',
'modified' => '2019-10-02 16:57:08',
'created' => '2019-10-02 16:16:55',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '3130',
'name' => 'Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization',
'authors' => 'Schanda J. et al.',
'description' => '<p>RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nervy homology regions 1-4 (NHR1 to N HR4). The NHR domains serve as docking sites for a variety of different proteins and in addition the N HR2 domain mediates tetramerization through hydrophobic and ionic /polar interactions . Tetramerization is essential for RUNX1/ETO oncogenic activity. Destabilization of the RUNX1/ETO high molecular weight complex abrogates RUNX1/ETO oncogenic activity. Using a structure-based virtual screening, we identified several small molecule inhibitors mimicking the tetramerization hot spot within the NHR2 domain of RUNX1/ETO. One of these compounds, 7.44, was of particular interest as it showed biological activity in vitro and in vivo.</p>',
'date' => '2017-02-02',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/28154087',
'doi' => '',
'modified' => '2017-02-23 11:58:56',
'created' => '2017-02-23 11:50:26',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '3087',
'name' => 'The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs',
'authors' => 'Mandoli A. et al.',
'description' => '<p>The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.</p>',
'date' => '2016-11-15',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/27851970',
'doi' => '',
'modified' => '2017-01-02 11:07:24',
'created' => '2017-01-02 11:07:24',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2989',
'name' => 'MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML',
'authors' => 'Vegi NM et al.',
'description' => '<p>Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.</p>',
'date' => '2016-07-12',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/27346355',
'doi' => '10.1016/j.celrep.2016.05.094',
'modified' => '2016-07-29 09:46:05',
'created' => '2016-07-29 09:46:05',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2884',
'name' => 'Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis',
'authors' => 'Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K',
'description' => '<p>DNA methylation is tightly regulated throughout mammalian development, and altered DNA methylation patterns are a general hallmark of cancer. The methylcytosine dioxygenase TET2 is frequently mutated in hematological disorders, including acute myeloid leukemia (AML), and has been suggested to protect CG dinucleotide (CpG) islands and promoters from aberrant DNA methylation. In this study, we present a novel <em>Tet2</em>-dependent leukemia mouse model that closely recapitulates gene expression profiles and hallmarks of human AML1-ETO-induced AML. Using this model, we show that the primary effect of <em>Tet2</em> loss in preleukemic hematopoietic cells is progressive and widespread DNA hypermethylation affecting up to 25% of active enhancer elements. In contrast, CpG island and promoter methylation does not change in a <em>Tet2</em>-dependent manner but increases relative to population doublings. We confirmed this specific enhancer hypermethylation phenotype in human AML patients with <em>TET2</em> mutations. Analysis of immediate gene expression changes reveals rapid deregulation of a large number of genes implicated in tumorigenesis, including many down-regulated tumor suppressor genes. Hence, we propose that TET2 prevents leukemic transformation by protecting enhancers from aberrant DNA methylation and that it is the combined silencing of several tumor suppressor genes in <em>TET2</em> mutated hematopoietic cells that contributes to increased stem cell proliferation and leukemogenesis.</p>',
'date' => '2015-04-17',
'pmid' => 'http://genesdev.cshlp.org/content/early/2015/04/15/gad.260174.115',
'doi' => '10.1101/gad.260174.115 ',
'modified' => '2016-04-07 09:39:29',
'created' => '2016-04-07 09:39:29',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '1847',
'name' => 'Immune evasion by oncogenic proteins of acute myeloid leukemia.',
'authors' => 'Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O',
'description' => 'PML-RARA and AML1-ETO are important oncogenic fusion proteins that play a central role in transformation to acute myeloid leukemia (AML). Whether these fusion proteins render the tumor cells with immune evasion properties is unknown. Here we show that both oncogenic proteins specifically downregulate the expression of CD48, a ligand of the natural killer (NK) cell activating receptor 2B4, thereby leading to decreased killing by NK cells. We demonstrate that this process is histone deacetylase (HDAC)-dependent, that it is mediated through the downregulation of CD48 messenger RNA, and that treatment with HDAC inhibitors (HDACi) restores the expression of CD48. Furthermore, by using chromatin immuoprecepitation (ChIP) experiments, we show that AML1-ETO directly interacts with CD48. Finally, we show that AML patients who are carrying these specific translocations have low expression of CD48.',
'date' => '2014-03-06',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/24449212',
'doi' => '',
'modified' => '2015-07-24 15:39:01',
'created' => '2015-07-24 15:39:01',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
'id' => '2590',
'name' => 'AML1-ETO antibody SDS GB en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-GB-en-GHS_1_0.pdf',
'countries' => 'GB',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '2592',
'name' => 'AML1-ETO antibody SDS US en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-US-en-GHS_1_0.pdf',
'countries' => 'US',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '2587',
'name' => 'AML1-ETO antibody SDS DE de',
'language' => 'de',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-DE-de-GHS_1_0.pdf',
'countries' => 'DE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2591',
'name' => 'AML1-ETO antibody SDS JP ja',
'language' => 'ja',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-JP-ja-GHS_1_0.pdf',
'countries' => 'JP',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2586',
'name' => 'AML1-ETO antibody SDS BE nl',
'language' => 'nl',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-nl-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '2585',
'name' => 'AML1-ETO antibody SDS BE fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-fr-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '2589',
'name' => 'AML1-ETO antibody SDS FR fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-FR-fr-GHS_1_0.pdf',
'countries' => 'FR',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 7 => array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
)
)
)
$meta_canonical = 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = true
$other_formats = array(
(int) 0 => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
)
$pro = array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'ProductsGroup' => array(
'id' => '313',
'product_id' => '3068',
'group_id' => '276'
)
)
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$country_code = 'US'
$other_format = array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
$img = 'banners/banner-cut_tag-chipmentation-500.jpg'
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$application = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
'id' => '5130',
'product_id' => '3068',
'application_id' => '43'
)
)
$slugs = array(
(int) 0 => 'chip-qpcr-antibodies'
)
$applications = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'locale' => 'eng'
)
$description = ''
$name = 'ChIP-qPCR (ab)'
$document = array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
'id' => '2881',
'product_id' => '3068',
'document_id' => '292'
)
)
$sds = array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
'id' => '4384',
'product_id' => '3068',
'safety_sheet_id' => '2588'
)
)
$publication = array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
'id' => '4493',
'product_id' => '3068',
'publication_id' => '997'
)
)
$externalLink = ' <a href="https://www.ncbi.nlm.nih.gov/pubmed/22983443" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
Notice (8): Undefined variable: header [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'product' => array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
[maximum depth reached]
),
'Master' => array(
[maximum depth reached]
),
'Product' => array(
[maximum depth reached]
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
)
),
'Category' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
)
),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
),
(int) 7 => array(
[maximum depth reached]
)
)
),
'meta_canonical' => 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
)
$language = 'en'
$meta_keywords = ''
$meta_description = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$meta_title = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$product = array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
'id' => '276',
'name' => 'C15310197',
'product_id' => '2135',
'modified' => '2020-05-12 11:15:05',
'created' => '2020-05-12 11:15:05'
),
'Master' => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
),
'Product' => array(
(int) 0 => array(
[maximum depth reached]
)
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
'id' => '19',
'position' => '10',
'parent_id' => '40',
'name' => 'WB',
'description' => '<p><strong>Western blot</strong> : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies.</p>
<p>Learn more about: <a href="https://www.diagenode.com/applications/western-blot">Loading control, MW marker visualization</a><em>. <br /></em></p>
<p><em></em>Check our selection of antibodies validated in Western blot.</p>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'western-blot-antibodies',
'meta_keywords' => ' Western Blot Antibodies ,western blot protocol,Western Blotting Products,Polyclonal antibodies ,monoclonal antibodies ',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for western blot applications',
'meta_title' => ' Western Blot - Monoclonal antibody - Polyclonal antibody | Diagenode',
'modified' => '2016-04-26 12:44:51',
'created' => '2015-01-07 09:20:00',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '20',
'position' => '10',
'parent_id' => '40',
'name' => 'ELISA',
'description' => '<div class="row">
<div class="small-12 medium-12 large-12 columns">Enzyme-linked immunosorbent assay.</div>
</div>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'elisa-antibodies',
'meta_keywords' => ' ELISA Antibodies,Monoclonal antibody, Polyclonal antibody',
'meta_description' => 'Diagenode offers Monoclonal & Polyclonal antibodies for ELISA applications',
'meta_title' => 'ELISA Antibodies - Monoclonal & Polyclonal antibody | Diagenode',
'modified' => '2016-01-13 12:21:41',
'created' => '2014-07-08 08:13:28',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '42',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-seq (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-seq-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP Sequencing applications',
'meta_title' => 'ChIP Sequencing Antibodies (ChIP-Seq) | Diagenode',
'modified' => '2016-01-20 11:06:19',
'created' => '2015-10-20 11:44:45',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
[maximum depth reached]
)
)
),
'Category' => array(
(int) 0 => array(
'id' => '17',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-seq grade antibodies',
'description' => '<p><b>Unparalleled ChIP-Seq results with the most rigorously validated antibodies</b></p>
<p><span style="font-weight: 400;">Diagenode provides leading solutions for epigenetic research. Because ChIP-seq is a widely-used technique, we validate our antibodies in ChIP and ChIP-seq experiments (in addition to conventional methods like Western blot, Dot blot, ELISA, and immunofluorescence) to provide the highest quality antibody. We standardize our validation and production to guarantee high product quality without technical bias. Diagenode guarantees ChIP-seq grade antibody performance under our suggested conditions.</span></p>
<div class="row">
<div class="small-12 medium-9 large-9 columns">
<p><strong>ChIP-seq profile</strong> of active (H3K4me3 and H3K36me3) and inactive (H3K27me3) marks using Diagenode antibodies.</p>
<img src="https://www.diagenode.com/img/categories/antibodies/chip-seq-grade-antibodies.png" /></div>
<div class="small-12 medium-3 large-3 columns">
<p><small> ChIP was performed on sheared chromatin from 100,000 K562 cells using iDeal ChIP-seq kit for Histones (cat. No. C01010051) with 1 µg of the Diagenode antibodies against H3K27me3 (cat. No. C15410195) and H3K4me3 (cat. No. C15410003), and 0.5 µg of the antibody against H3K36me3 (cat. No. C15410192). The IP'd DNA was subsequently analysed on an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 36 bp tags were aligned to the human genome using the ELAND algorithm. The figure shows the signal distribution along the complete sequence of human chromosome 3, a zoomin to a 10 Mb region and a further zoomin to a 1.5 Mb region. </small></p>
</div>
</div>
<p>Diagenode’s highly validated antibodies:</p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-seq-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-seq grade antibodies,polyclonal antibody,WB, ELISA, ChIP-seq (ab), ChIP-qPCR (ab)',
'meta_description' => 'Diagenode Offers Wide Range of Validated ChIP-Seq Grade Antibodies for Unparalleled ChIP-Seq Results',
'meta_title' => 'Chromatin Immunoprecipitation ChIP-Seq Grade Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:22',
'created' => '2015-02-16 02:24:01',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 1 => array(
'id' => '127',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-grade antibodies',
'description' => '<div class="row">
<div class="small-12 columns"><center></center>
<p><br />Chromatin immunoprecipitation (<b>ChIP</b>) is a technique to study the associations of proteins with the specific genomic regions in intact cells. One of the most important steps of this protocol is the immunoprecipitation of targeted protein using the antibody specifically recognizing it. The quality of antibodies used in ChIP is essential for the success of the experiment. Diagenode offers extensively validated ChIP-grade antibodies, confirmed for their specificity, and high level of performance in ChIP. Each batch is validated, and batch-specific data are available on the website.</p>
<p></p>
</div>
</div>
<p><strong>ChIP results</strong> obtained with the antibody directed against H3K4me3 (Cat. No. <a href="../p/h3k4me3-polyclonal-antibody-premium-50-ug-50-ul">C15410003</a>). </p>
<div class="row">
<div class="small-12 medium-6 large-6 columns"><img src="https://www.diagenode.com/img/product/antibodies/C15410003-fig1-ChIP.jpg" alt="" width="400" height="315" /> </div>
<div class="small-12 medium-6 large-6 columns">
<p></p>
<p></p>
<p></p>
</div>
</div>
<p></p>
<p>Our aim at Diagenode is to offer the largest collection of highly specific <strong>ChIP-grade antibodies</strong>. We add new antibodies monthly. Find your ChIP-grade antibody in the list below and check more information about tested applications, extensive validation data, and product information.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-grade antibodies, polyclonal antibody, monoclonal antibody, Diagenode',
'meta_description' => 'Diagenode Offers Extensively Validated ChIP-Grade Antibodies, Confirmed for their Specificity, and high level of Performance in Chromatin Immunoprecipitation ChIP',
'meta_title' => 'Chromatin immunoprecipitation ChIP-grade antibodies | Diagenode',
'modified' => '2024-11-19 17:27:07',
'created' => '2017-02-14 11:16:04',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 2 => array(
'id' => '102',
'position' => '1',
'parent_id' => '4',
'name' => 'Sample size antibodies',
'description' => '<h1><strong>Validated epigenetics antibodies</strong> – care for a sample?<br /> </h1>
<p>Diagenode has partnered with leading epigenetics experts and numerous epigenetics consortiums to bring to you a validated and comprehensive collection of epigenetic antibodies. As an expert in epigenetics, we are committed to offering highly-specific antibodies validated for ChIP/ChIP-seq and many other applications. All batch-specific validation data is available on our website.<br /><a href="../categories/antibodies">Read about our expertise in antibody production</a>.</p>
<ul>
<li><strong>Focused</strong> - Diagenode's selection of antibodies is exclusively dedicated for epigenetic research. <a title="See the full collection." href="../categories/all-antibodies">See the full collection.</a></li>
<li><strong>Strict quality standards</strong> with rigorous QC and validation</li>
<li><strong>Classified</strong> based on level of validation for flexibility of application</li>
</ul>
<p>Existing sample sizes are listed below. We will soon expand our collection. Are you looking for a sample size of another antibody? Just <a href="mailto:agnieszka.zelisko@diagenode.com?Subject=Sample%20Size%20Request" target="_top">Contact us</a>.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => true,
'is_antibody' => true,
'slug' => 'sample-size-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => '5-hmC monoclonal antibody,CRISPR/Cas9 polyclonal antibody ,H3K36me3 polyclonal antibody,diagenode',
'meta_description' => 'Diagenode offers sample volume on selected antibodies for researchers to test, validate and provide confidence and flexibility in choosing from our wide range of antibodies ',
'meta_title' => 'Sample-size Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:05',
'created' => '2015-10-27 12:13:34',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 3 => array(
'id' => '30',
'position' => '50',
'parent_id' => '4',
'name' => 'Transcription',
'description' => '<p><span style="font-weight: 400;">The list of Diagenode’s highly specific antibodies for transcription studies includes the antibodies against many transcription factors and nuclear receptors. Check the list below to see our targets.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li><span style="font-weight: 400;"> Highly sensitive and specific</span></li>
<li><span style="font-weight: 400;"> Cost-effective (requires less antibody per reaction)</span></li>
<li><span style="font-weight: 400;"> Batch-specific data is available on the website</span></li>
<li><span style="font-weight: 400;"> Expert technical support</span></li>
<li><span style="font-weight: 400;"> Sample sizes available</span></li>
<li><span style="font-weight: 400;"> 100% satisfaction guarantee</span></li>
</ul>',
'no_promo' => false,
'in_menu' => false,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'transcription-factor',
'cookies_tag_id' => null,
'meta_keywords' => ' Transcription factor antibodies,monoclonal antibodies,polyclonal antibodies',
'meta_description' => 'Diagenode offers polyclonal and monoclonal antibodies for Transcription studie',
'meta_title' => 'Transcription factor Antibodies | Diagenode',
'modified' => '2020-07-06 12:59:19',
'created' => '2015-03-12 10:20:08',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 4 => array(
'id' => '103',
'position' => '0',
'parent_id' => '4',
'name' => 'All antibodies',
'description' => '<p><span style="font-weight: 400;">All Diagenode’s antibodies are listed below. Please, use our Quick search field to find the antibody of interest by target name, application, purity.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'all-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'Antibodies,Premium Antibodies,Classic,Pioneer',
'meta_description' => 'Diagenode Offers Strict quality standards with Rigorous QC and validated Antibodies. Classified based on level of validation for flexibility of Application. Comprehensive selection of histone and non-histone Antibodies',
'meta_title' => 'Diagenode's selection of Antibodies is exclusively dedicated for Epigenetic Research | Diagenode',
'modified' => '2019-07-03 10:55:44',
'created' => '2015-11-02 14:49:22',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
)
),
'Document' => array(
(int) 0 => array(
'id' => '11',
'name' => 'Antibodies you can trust',
'description' => '<p style="text-align: justify;"><span>Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of large sets of genome-wide sequencing data. ChIP sequencing (ChIP-seq) has now become the gold standard method for chromatin studies, given the accuracy and coverage scale of the approach over other methods. Successful ChIP-seq, however, requires a higher level of experimental accuracy and consistency in all steps of ChIP than ever before. Particularly crucial is the quality of ChIP antibodies. </span></p>',
'image_id' => null,
'type' => 'Poster',
'url' => 'files/posters/Antibodies_you_can_trust_Poster.pdf',
'slug' => 'antibodies-you-can-trust-poster',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2015-10-01 20:18:31',
'created' => '2015-07-03 16:05:15',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '38',
'name' => 'Epigenetic Antibodies Brochure',
'description' => '<p>More than in any other immuoprecipitation assays, quality antibodies are critical tools in many epigenetics experiments. Since 10 years, Diagenode has developed the most stringent quality production available on the market for antibodies exclusively focused on epigenetic uses. All our antibodies have been qualified to work in epigenetic applications.</p>',
'image_id' => null,
'type' => 'Brochure',
'url' => 'files/brochures/Epigenetic_Antibodies_Brochure.pdf',
'slug' => 'epigenetic-antibodies-brochure',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2016-06-15 11:24:06',
'created' => '2015-07-03 16:05:27',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '1783',
'name' => 'product/antibodies/chipseq-grade-ab-icon.png',
'alt' => 'ChIP-seq Grade',
'modified' => '2020-11-27 07:04:40',
'created' => '2018-03-15 15:54:09',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '3778',
'name' => 'RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.',
'authors' => 'Ptasinska A, Pickin A, Assi SA, Chin PS, Ames L, Avellino R, Gröschel S, Delwel R, Cockerill PN, Osborne CS, Bonifer C',
'description' => '<p>Acute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maintenance of t(8;21) AML is dependent on RUNX1-ETO expression. Its depletion causes extensive changes in transcription factor binding, as well as gene expression, and initiates myeloid differentiation. However, how these processes are connected within a gene regulatory network is unclear. To address this question, we performed Promoter-Capture Hi-C assays, with or without RUNX1-ETO depletion and assigned interacting cis-regulatory elements to their respective genes. To construct a RUNX1-ETO-dependent gene regulatory network maintaining AML, we integrated cis-regulatory element interactions with gene expression and transcription factor binding data. This analysis shows that RUNX1-ETO participates in cis-regulatory element interactions. However, differential interactions following RUNX1-ETO depletion are driven by alterations in the binding of RUNX1-ETO-regulated transcription factors.</p>',
'date' => '2019-09-17',
'pmid' => 'http://www.pubmed.gov/31533028',
'doi' => '10.1016/j.celrep.2019.08.040',
'modified' => '2019-10-02 16:57:08',
'created' => '2019-10-02 16:16:55',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '3130',
'name' => 'Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization',
'authors' => 'Schanda J. et al.',
'description' => '<p>RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nervy homology regions 1-4 (NHR1 to N HR4). The NHR domains serve as docking sites for a variety of different proteins and in addition the N HR2 domain mediates tetramerization through hydrophobic and ionic /polar interactions . Tetramerization is essential for RUNX1/ETO oncogenic activity. Destabilization of the RUNX1/ETO high molecular weight complex abrogates RUNX1/ETO oncogenic activity. Using a structure-based virtual screening, we identified several small molecule inhibitors mimicking the tetramerization hot spot within the NHR2 domain of RUNX1/ETO. One of these compounds, 7.44, was of particular interest as it showed biological activity in vitro and in vivo.</p>',
'date' => '2017-02-02',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/28154087',
'doi' => '',
'modified' => '2017-02-23 11:58:56',
'created' => '2017-02-23 11:50:26',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '3087',
'name' => 'The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs',
'authors' => 'Mandoli A. et al.',
'description' => '<p>The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.</p>',
'date' => '2016-11-15',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/27851970',
'doi' => '',
'modified' => '2017-01-02 11:07:24',
'created' => '2017-01-02 11:07:24',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2989',
'name' => 'MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML',
'authors' => 'Vegi NM et al.',
'description' => '<p>Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.</p>',
'date' => '2016-07-12',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/27346355',
'doi' => '10.1016/j.celrep.2016.05.094',
'modified' => '2016-07-29 09:46:05',
'created' => '2016-07-29 09:46:05',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2884',
'name' => 'Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis',
'authors' => 'Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K',
'description' => '<p>DNA methylation is tightly regulated throughout mammalian development, and altered DNA methylation patterns are a general hallmark of cancer. The methylcytosine dioxygenase TET2 is frequently mutated in hematological disorders, including acute myeloid leukemia (AML), and has been suggested to protect CG dinucleotide (CpG) islands and promoters from aberrant DNA methylation. In this study, we present a novel <em>Tet2</em>-dependent leukemia mouse model that closely recapitulates gene expression profiles and hallmarks of human AML1-ETO-induced AML. Using this model, we show that the primary effect of <em>Tet2</em> loss in preleukemic hematopoietic cells is progressive and widespread DNA hypermethylation affecting up to 25% of active enhancer elements. In contrast, CpG island and promoter methylation does not change in a <em>Tet2</em>-dependent manner but increases relative to population doublings. We confirmed this specific enhancer hypermethylation phenotype in human AML patients with <em>TET2</em> mutations. Analysis of immediate gene expression changes reveals rapid deregulation of a large number of genes implicated in tumorigenesis, including many down-regulated tumor suppressor genes. Hence, we propose that TET2 prevents leukemic transformation by protecting enhancers from aberrant DNA methylation and that it is the combined silencing of several tumor suppressor genes in <em>TET2</em> mutated hematopoietic cells that contributes to increased stem cell proliferation and leukemogenesis.</p>',
'date' => '2015-04-17',
'pmid' => 'http://genesdev.cshlp.org/content/early/2015/04/15/gad.260174.115',
'doi' => '10.1101/gad.260174.115 ',
'modified' => '2016-04-07 09:39:29',
'created' => '2016-04-07 09:39:29',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '1847',
'name' => 'Immune evasion by oncogenic proteins of acute myeloid leukemia.',
'authors' => 'Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O',
'description' => 'PML-RARA and AML1-ETO are important oncogenic fusion proteins that play a central role in transformation to acute myeloid leukemia (AML). Whether these fusion proteins render the tumor cells with immune evasion properties is unknown. Here we show that both oncogenic proteins specifically downregulate the expression of CD48, a ligand of the natural killer (NK) cell activating receptor 2B4, thereby leading to decreased killing by NK cells. We demonstrate that this process is histone deacetylase (HDAC)-dependent, that it is mediated through the downregulation of CD48 messenger RNA, and that treatment with HDAC inhibitors (HDACi) restores the expression of CD48. Furthermore, by using chromatin immuoprecepitation (ChIP) experiments, we show that AML1-ETO directly interacts with CD48. Finally, we show that AML patients who are carrying these specific translocations have low expression of CD48.',
'date' => '2014-03-06',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/24449212',
'doi' => '',
'modified' => '2015-07-24 15:39:01',
'created' => '2015-07-24 15:39:01',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
'id' => '2590',
'name' => 'AML1-ETO antibody SDS GB en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-GB-en-GHS_1_0.pdf',
'countries' => 'GB',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '2592',
'name' => 'AML1-ETO antibody SDS US en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-US-en-GHS_1_0.pdf',
'countries' => 'US',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '2587',
'name' => 'AML1-ETO antibody SDS DE de',
'language' => 'de',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-DE-de-GHS_1_0.pdf',
'countries' => 'DE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2591',
'name' => 'AML1-ETO antibody SDS JP ja',
'language' => 'ja',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-JP-ja-GHS_1_0.pdf',
'countries' => 'JP',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2586',
'name' => 'AML1-ETO antibody SDS BE nl',
'language' => 'nl',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-nl-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '2585',
'name' => 'AML1-ETO antibody SDS BE fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-fr-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '2589',
'name' => 'AML1-ETO antibody SDS FR fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-FR-fr-GHS_1_0.pdf',
'countries' => 'FR',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 7 => array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
)
)
)
$meta_canonical = 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = true
$other_formats = array(
(int) 0 => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
)
$pro = array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'ProductsGroup' => array(
'id' => '313',
'product_id' => '3068',
'group_id' => '276'
)
)
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$country_code = 'US'
$other_format = array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
$img = 'banners/banner-cut_tag-chipmentation-500.jpg'
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$application = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
'id' => '5130',
'product_id' => '3068',
'application_id' => '43'
)
)
$slugs = array(
(int) 0 => 'chip-qpcr-antibodies'
)
$applications = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'locale' => 'eng'
)
$description = ''
$name = 'ChIP-qPCR (ab)'
$document = array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
'id' => '2881',
'product_id' => '3068',
'document_id' => '292'
)
)
$sds = array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
'id' => '4384',
'product_id' => '3068',
'safety_sheet_id' => '2588'
)
)
$publication = array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
'id' => '4493',
'product_id' => '3068',
'publication_id' => '997'
)
)
$externalLink = ' <a href="https://www.ncbi.nlm.nih.gov/pubmed/22983443" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
Notice (8): Undefined variable: message [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'product' => array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
[maximum depth reached]
),
'Master' => array(
[maximum depth reached]
),
'Product' => array(
[maximum depth reached]
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
)
),
'Category' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
)
),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
),
(int) 7 => array(
[maximum depth reached]
)
)
),
'meta_canonical' => 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
)
$language = 'en'
$meta_keywords = ''
$meta_description = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$meta_title = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$product = array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
'id' => '276',
'name' => 'C15310197',
'product_id' => '2135',
'modified' => '2020-05-12 11:15:05',
'created' => '2020-05-12 11:15:05'
),
'Master' => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
),
'Product' => array(
(int) 0 => array(
[maximum depth reached]
)
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
'id' => '19',
'position' => '10',
'parent_id' => '40',
'name' => 'WB',
'description' => '<p><strong>Western blot</strong> : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies.</p>
<p>Learn more about: <a href="https://www.diagenode.com/applications/western-blot">Loading control, MW marker visualization</a><em>. <br /></em></p>
<p><em></em>Check our selection of antibodies validated in Western blot.</p>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'western-blot-antibodies',
'meta_keywords' => ' Western Blot Antibodies ,western blot protocol,Western Blotting Products,Polyclonal antibodies ,monoclonal antibodies ',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for western blot applications',
'meta_title' => ' Western Blot - Monoclonal antibody - Polyclonal antibody | Diagenode',
'modified' => '2016-04-26 12:44:51',
'created' => '2015-01-07 09:20:00',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '20',
'position' => '10',
'parent_id' => '40',
'name' => 'ELISA',
'description' => '<div class="row">
<div class="small-12 medium-12 large-12 columns">Enzyme-linked immunosorbent assay.</div>
</div>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'elisa-antibodies',
'meta_keywords' => ' ELISA Antibodies,Monoclonal antibody, Polyclonal antibody',
'meta_description' => 'Diagenode offers Monoclonal & Polyclonal antibodies for ELISA applications',
'meta_title' => 'ELISA Antibodies - Monoclonal & Polyclonal antibody | Diagenode',
'modified' => '2016-01-13 12:21:41',
'created' => '2014-07-08 08:13:28',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '42',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-seq (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-seq-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP Sequencing applications',
'meta_title' => 'ChIP Sequencing Antibodies (ChIP-Seq) | Diagenode',
'modified' => '2016-01-20 11:06:19',
'created' => '2015-10-20 11:44:45',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
[maximum depth reached]
)
)
),
'Category' => array(
(int) 0 => array(
'id' => '17',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-seq grade antibodies',
'description' => '<p><b>Unparalleled ChIP-Seq results with the most rigorously validated antibodies</b></p>
<p><span style="font-weight: 400;">Diagenode provides leading solutions for epigenetic research. Because ChIP-seq is a widely-used technique, we validate our antibodies in ChIP and ChIP-seq experiments (in addition to conventional methods like Western blot, Dot blot, ELISA, and immunofluorescence) to provide the highest quality antibody. We standardize our validation and production to guarantee high product quality without technical bias. Diagenode guarantees ChIP-seq grade antibody performance under our suggested conditions.</span></p>
<div class="row">
<div class="small-12 medium-9 large-9 columns">
<p><strong>ChIP-seq profile</strong> of active (H3K4me3 and H3K36me3) and inactive (H3K27me3) marks using Diagenode antibodies.</p>
<img src="https://www.diagenode.com/img/categories/antibodies/chip-seq-grade-antibodies.png" /></div>
<div class="small-12 medium-3 large-3 columns">
<p><small> ChIP was performed on sheared chromatin from 100,000 K562 cells using iDeal ChIP-seq kit for Histones (cat. No. C01010051) with 1 µg of the Diagenode antibodies against H3K27me3 (cat. No. C15410195) and H3K4me3 (cat. No. C15410003), and 0.5 µg of the antibody against H3K36me3 (cat. No. C15410192). The IP'd DNA was subsequently analysed on an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 36 bp tags were aligned to the human genome using the ELAND algorithm. The figure shows the signal distribution along the complete sequence of human chromosome 3, a zoomin to a 10 Mb region and a further zoomin to a 1.5 Mb region. </small></p>
</div>
</div>
<p>Diagenode’s highly validated antibodies:</p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-seq-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-seq grade antibodies,polyclonal antibody,WB, ELISA, ChIP-seq (ab), ChIP-qPCR (ab)',
'meta_description' => 'Diagenode Offers Wide Range of Validated ChIP-Seq Grade Antibodies for Unparalleled ChIP-Seq Results',
'meta_title' => 'Chromatin Immunoprecipitation ChIP-Seq Grade Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:22',
'created' => '2015-02-16 02:24:01',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 1 => array(
'id' => '127',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-grade antibodies',
'description' => '<div class="row">
<div class="small-12 columns"><center></center>
<p><br />Chromatin immunoprecipitation (<b>ChIP</b>) is a technique to study the associations of proteins with the specific genomic regions in intact cells. One of the most important steps of this protocol is the immunoprecipitation of targeted protein using the antibody specifically recognizing it. The quality of antibodies used in ChIP is essential for the success of the experiment. Diagenode offers extensively validated ChIP-grade antibodies, confirmed for their specificity, and high level of performance in ChIP. Each batch is validated, and batch-specific data are available on the website.</p>
<p></p>
</div>
</div>
<p><strong>ChIP results</strong> obtained with the antibody directed against H3K4me3 (Cat. No. <a href="../p/h3k4me3-polyclonal-antibody-premium-50-ug-50-ul">C15410003</a>). </p>
<div class="row">
<div class="small-12 medium-6 large-6 columns"><img src="https://www.diagenode.com/img/product/antibodies/C15410003-fig1-ChIP.jpg" alt="" width="400" height="315" /> </div>
<div class="small-12 medium-6 large-6 columns">
<p></p>
<p></p>
<p></p>
</div>
</div>
<p></p>
<p>Our aim at Diagenode is to offer the largest collection of highly specific <strong>ChIP-grade antibodies</strong>. We add new antibodies monthly. Find your ChIP-grade antibody in the list below and check more information about tested applications, extensive validation data, and product information.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-grade antibodies, polyclonal antibody, monoclonal antibody, Diagenode',
'meta_description' => 'Diagenode Offers Extensively Validated ChIP-Grade Antibodies, Confirmed for their Specificity, and high level of Performance in Chromatin Immunoprecipitation ChIP',
'meta_title' => 'Chromatin immunoprecipitation ChIP-grade antibodies | Diagenode',
'modified' => '2024-11-19 17:27:07',
'created' => '2017-02-14 11:16:04',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 2 => array(
'id' => '102',
'position' => '1',
'parent_id' => '4',
'name' => 'Sample size antibodies',
'description' => '<h1><strong>Validated epigenetics antibodies</strong> – care for a sample?<br /> </h1>
<p>Diagenode has partnered with leading epigenetics experts and numerous epigenetics consortiums to bring to you a validated and comprehensive collection of epigenetic antibodies. As an expert in epigenetics, we are committed to offering highly-specific antibodies validated for ChIP/ChIP-seq and many other applications. All batch-specific validation data is available on our website.<br /><a href="../categories/antibodies">Read about our expertise in antibody production</a>.</p>
<ul>
<li><strong>Focused</strong> - Diagenode's selection of antibodies is exclusively dedicated for epigenetic research. <a title="See the full collection." href="../categories/all-antibodies">See the full collection.</a></li>
<li><strong>Strict quality standards</strong> with rigorous QC and validation</li>
<li><strong>Classified</strong> based on level of validation for flexibility of application</li>
</ul>
<p>Existing sample sizes are listed below. We will soon expand our collection. Are you looking for a sample size of another antibody? Just <a href="mailto:agnieszka.zelisko@diagenode.com?Subject=Sample%20Size%20Request" target="_top">Contact us</a>.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => true,
'is_antibody' => true,
'slug' => 'sample-size-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => '5-hmC monoclonal antibody,CRISPR/Cas9 polyclonal antibody ,H3K36me3 polyclonal antibody,diagenode',
'meta_description' => 'Diagenode offers sample volume on selected antibodies for researchers to test, validate and provide confidence and flexibility in choosing from our wide range of antibodies ',
'meta_title' => 'Sample-size Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:05',
'created' => '2015-10-27 12:13:34',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 3 => array(
'id' => '30',
'position' => '50',
'parent_id' => '4',
'name' => 'Transcription',
'description' => '<p><span style="font-weight: 400;">The list of Diagenode’s highly specific antibodies for transcription studies includes the antibodies against many transcription factors and nuclear receptors. Check the list below to see our targets.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li><span style="font-weight: 400;"> Highly sensitive and specific</span></li>
<li><span style="font-weight: 400;"> Cost-effective (requires less antibody per reaction)</span></li>
<li><span style="font-weight: 400;"> Batch-specific data is available on the website</span></li>
<li><span style="font-weight: 400;"> Expert technical support</span></li>
<li><span style="font-weight: 400;"> Sample sizes available</span></li>
<li><span style="font-weight: 400;"> 100% satisfaction guarantee</span></li>
</ul>',
'no_promo' => false,
'in_menu' => false,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'transcription-factor',
'cookies_tag_id' => null,
'meta_keywords' => ' Transcription factor antibodies,monoclonal antibodies,polyclonal antibodies',
'meta_description' => 'Diagenode offers polyclonal and monoclonal antibodies for Transcription studie',
'meta_title' => 'Transcription factor Antibodies | Diagenode',
'modified' => '2020-07-06 12:59:19',
'created' => '2015-03-12 10:20:08',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 4 => array(
'id' => '103',
'position' => '0',
'parent_id' => '4',
'name' => 'All antibodies',
'description' => '<p><span style="font-weight: 400;">All Diagenode’s antibodies are listed below. Please, use our Quick search field to find the antibody of interest by target name, application, purity.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'all-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'Antibodies,Premium Antibodies,Classic,Pioneer',
'meta_description' => 'Diagenode Offers Strict quality standards with Rigorous QC and validated Antibodies. Classified based on level of validation for flexibility of Application. Comprehensive selection of histone and non-histone Antibodies',
'meta_title' => 'Diagenode's selection of Antibodies is exclusively dedicated for Epigenetic Research | Diagenode',
'modified' => '2019-07-03 10:55:44',
'created' => '2015-11-02 14:49:22',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
)
),
'Document' => array(
(int) 0 => array(
'id' => '11',
'name' => 'Antibodies you can trust',
'description' => '<p style="text-align: justify;"><span>Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of large sets of genome-wide sequencing data. ChIP sequencing (ChIP-seq) has now become the gold standard method for chromatin studies, given the accuracy and coverage scale of the approach over other methods. Successful ChIP-seq, however, requires a higher level of experimental accuracy and consistency in all steps of ChIP than ever before. Particularly crucial is the quality of ChIP antibodies. </span></p>',
'image_id' => null,
'type' => 'Poster',
'url' => 'files/posters/Antibodies_you_can_trust_Poster.pdf',
'slug' => 'antibodies-you-can-trust-poster',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2015-10-01 20:18:31',
'created' => '2015-07-03 16:05:15',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '38',
'name' => 'Epigenetic Antibodies Brochure',
'description' => '<p>More than in any other immuoprecipitation assays, quality antibodies are critical tools in many epigenetics experiments. Since 10 years, Diagenode has developed the most stringent quality production available on the market for antibodies exclusively focused on epigenetic uses. All our antibodies have been qualified to work in epigenetic applications.</p>',
'image_id' => null,
'type' => 'Brochure',
'url' => 'files/brochures/Epigenetic_Antibodies_Brochure.pdf',
'slug' => 'epigenetic-antibodies-brochure',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2016-06-15 11:24:06',
'created' => '2015-07-03 16:05:27',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '1783',
'name' => 'product/antibodies/chipseq-grade-ab-icon.png',
'alt' => 'ChIP-seq Grade',
'modified' => '2020-11-27 07:04:40',
'created' => '2018-03-15 15:54:09',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '3778',
'name' => 'RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.',
'authors' => 'Ptasinska A, Pickin A, Assi SA, Chin PS, Ames L, Avellino R, Gröschel S, Delwel R, Cockerill PN, Osborne CS, Bonifer C',
'description' => '<p>Acute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maintenance of t(8;21) AML is dependent on RUNX1-ETO expression. Its depletion causes extensive changes in transcription factor binding, as well as gene expression, and initiates myeloid differentiation. However, how these processes are connected within a gene regulatory network is unclear. To address this question, we performed Promoter-Capture Hi-C assays, with or without RUNX1-ETO depletion and assigned interacting cis-regulatory elements to their respective genes. To construct a RUNX1-ETO-dependent gene regulatory network maintaining AML, we integrated cis-regulatory element interactions with gene expression and transcription factor binding data. This analysis shows that RUNX1-ETO participates in cis-regulatory element interactions. However, differential interactions following RUNX1-ETO depletion are driven by alterations in the binding of RUNX1-ETO-regulated transcription factors.</p>',
'date' => '2019-09-17',
'pmid' => 'http://www.pubmed.gov/31533028',
'doi' => '10.1016/j.celrep.2019.08.040',
'modified' => '2019-10-02 16:57:08',
'created' => '2019-10-02 16:16:55',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '3130',
'name' => 'Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization',
'authors' => 'Schanda J. et al.',
'description' => '<p>RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nervy homology regions 1-4 (NHR1 to N HR4). The NHR domains serve as docking sites for a variety of different proteins and in addition the N HR2 domain mediates tetramerization through hydrophobic and ionic /polar interactions . Tetramerization is essential for RUNX1/ETO oncogenic activity. Destabilization of the RUNX1/ETO high molecular weight complex abrogates RUNX1/ETO oncogenic activity. Using a structure-based virtual screening, we identified several small molecule inhibitors mimicking the tetramerization hot spot within the NHR2 domain of RUNX1/ETO. One of these compounds, 7.44, was of particular interest as it showed biological activity in vitro and in vivo.</p>',
'date' => '2017-02-02',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/28154087',
'doi' => '',
'modified' => '2017-02-23 11:58:56',
'created' => '2017-02-23 11:50:26',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '3087',
'name' => 'The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs',
'authors' => 'Mandoli A. et al.',
'description' => '<p>The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.</p>',
'date' => '2016-11-15',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/27851970',
'doi' => '',
'modified' => '2017-01-02 11:07:24',
'created' => '2017-01-02 11:07:24',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2989',
'name' => 'MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML',
'authors' => 'Vegi NM et al.',
'description' => '<p>Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.</p>',
'date' => '2016-07-12',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/27346355',
'doi' => '10.1016/j.celrep.2016.05.094',
'modified' => '2016-07-29 09:46:05',
'created' => '2016-07-29 09:46:05',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2884',
'name' => 'Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis',
'authors' => 'Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K',
'description' => '<p>DNA methylation is tightly regulated throughout mammalian development, and altered DNA methylation patterns are a general hallmark of cancer. The methylcytosine dioxygenase TET2 is frequently mutated in hematological disorders, including acute myeloid leukemia (AML), and has been suggested to protect CG dinucleotide (CpG) islands and promoters from aberrant DNA methylation. In this study, we present a novel <em>Tet2</em>-dependent leukemia mouse model that closely recapitulates gene expression profiles and hallmarks of human AML1-ETO-induced AML. Using this model, we show that the primary effect of <em>Tet2</em> loss in preleukemic hematopoietic cells is progressive and widespread DNA hypermethylation affecting up to 25% of active enhancer elements. In contrast, CpG island and promoter methylation does not change in a <em>Tet2</em>-dependent manner but increases relative to population doublings. We confirmed this specific enhancer hypermethylation phenotype in human AML patients with <em>TET2</em> mutations. Analysis of immediate gene expression changes reveals rapid deregulation of a large number of genes implicated in tumorigenesis, including many down-regulated tumor suppressor genes. Hence, we propose that TET2 prevents leukemic transformation by protecting enhancers from aberrant DNA methylation and that it is the combined silencing of several tumor suppressor genes in <em>TET2</em> mutated hematopoietic cells that contributes to increased stem cell proliferation and leukemogenesis.</p>',
'date' => '2015-04-17',
'pmid' => 'http://genesdev.cshlp.org/content/early/2015/04/15/gad.260174.115',
'doi' => '10.1101/gad.260174.115 ',
'modified' => '2016-04-07 09:39:29',
'created' => '2016-04-07 09:39:29',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '1847',
'name' => 'Immune evasion by oncogenic proteins of acute myeloid leukemia.',
'authors' => 'Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O',
'description' => 'PML-RARA and AML1-ETO are important oncogenic fusion proteins that play a central role in transformation to acute myeloid leukemia (AML). Whether these fusion proteins render the tumor cells with immune evasion properties is unknown. Here we show that both oncogenic proteins specifically downregulate the expression of CD48, a ligand of the natural killer (NK) cell activating receptor 2B4, thereby leading to decreased killing by NK cells. We demonstrate that this process is histone deacetylase (HDAC)-dependent, that it is mediated through the downregulation of CD48 messenger RNA, and that treatment with HDAC inhibitors (HDACi) restores the expression of CD48. Furthermore, by using chromatin immuoprecepitation (ChIP) experiments, we show that AML1-ETO directly interacts with CD48. Finally, we show that AML patients who are carrying these specific translocations have low expression of CD48.',
'date' => '2014-03-06',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/24449212',
'doi' => '',
'modified' => '2015-07-24 15:39:01',
'created' => '2015-07-24 15:39:01',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
'id' => '2590',
'name' => 'AML1-ETO antibody SDS GB en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-GB-en-GHS_1_0.pdf',
'countries' => 'GB',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '2592',
'name' => 'AML1-ETO antibody SDS US en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-US-en-GHS_1_0.pdf',
'countries' => 'US',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '2587',
'name' => 'AML1-ETO antibody SDS DE de',
'language' => 'de',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-DE-de-GHS_1_0.pdf',
'countries' => 'DE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2591',
'name' => 'AML1-ETO antibody SDS JP ja',
'language' => 'ja',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-JP-ja-GHS_1_0.pdf',
'countries' => 'JP',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2586',
'name' => 'AML1-ETO antibody SDS BE nl',
'language' => 'nl',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-nl-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '2585',
'name' => 'AML1-ETO antibody SDS BE fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-fr-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '2589',
'name' => 'AML1-ETO antibody SDS FR fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-FR-fr-GHS_1_0.pdf',
'countries' => 'FR',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 7 => array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
)
)
)
$meta_canonical = 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = true
$other_formats = array(
(int) 0 => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
)
$pro = array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'ProductsGroup' => array(
'id' => '313',
'product_id' => '3068',
'group_id' => '276'
)
)
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$country_code = 'US'
$other_format = array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
$img = 'banners/banner-cut_tag-chipmentation-500.jpg'
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$application = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
'id' => '5130',
'product_id' => '3068',
'application_id' => '43'
)
)
$slugs = array(
(int) 0 => 'chip-qpcr-antibodies'
)
$applications = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'locale' => 'eng'
)
$description = ''
$name = 'ChIP-qPCR (ab)'
$document = array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
'id' => '2881',
'product_id' => '3068',
'document_id' => '292'
)
)
$sds = array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
'id' => '4384',
'product_id' => '3068',
'safety_sheet_id' => '2588'
)
)
$publication = array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
'id' => '4493',
'product_id' => '3068',
'publication_id' => '997'
)
)
$externalLink = ' <a href="https://www.ncbi.nlm.nih.gov/pubmed/22983443" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
Notice (8): Undefined variable: campaign_id [APP/View/Products/view.ctp, line 755]Code Context<!-- BEGIN: REQUEST_FORM MODAL -->
<div id="request_formModal" class="reveal-modal medium" data-reveal aria-labelledby="modalTitle" aria-hidden="true" role="dialog">
<?= $this->element('Forms/simple_form', array('solution_of_interest' => $solution_of_interest, 'header' => $header, 'message' => $message, 'campaign_id' => $campaign_id)) ?>
$viewFile = '/home/website-server/www/app/View/Products/view.ctp'
$dataForView = array(
'language' => 'en',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'product' => array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
[maximum depth reached]
),
'Master' => array(
[maximum depth reached]
),
'Product' => array(
[maximum depth reached]
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
)
),
'Category' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
)
),
'Document' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
[maximum depth reached]
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
[maximum depth reached]
),
(int) 1 => array(
[maximum depth reached]
),
(int) 2 => array(
[maximum depth reached]
),
(int) 3 => array(
[maximum depth reached]
),
(int) 4 => array(
[maximum depth reached]
),
(int) 5 => array(
[maximum depth reached]
),
(int) 6 => array(
[maximum depth reached]
),
(int) 7 => array(
[maximum depth reached]
)
)
),
'meta_canonical' => 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
)
$language = 'en'
$meta_keywords = ''
$meta_description = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$meta_title = 'AML1-ETO Antibody - ChIP-seq Grade (sample size)'
$product = array(
'Product' => array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'locale' => 'eng'
),
'Antibody' => array(
'host' => '*****',
'id' => '65',
'name' => 'AML1-ETO polyclonal antibody',
'description' => 'This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.',
'clonality' => '',
'isotype' => '',
'lot' => 'A706-002',
'concentration' => 'not determined',
'reactivity' => 'Human',
'type' => 'Polyclonal',
'purity' => 'Whole antiserum',
'classification' => 'Classic',
'application_table' => '<table>
<thead>
<tr>
<th>Applications</th>
<th>Suggested dilution</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>ChIP/ChIP-seq <sup>*</sup></td>
<td>4 μl/ChIP</td>
<td>Fig 1, 2</td>
</tr>
<tr>
<td>ELISA</td>
<td>1:500</td>
<td>Fig 3</td>
</tr>
<tr>
<td>Western Blotting</td>
<td>1:1,000</td>
<td>Fig 4</td>
</tr>
</tbody>
</table>
<p><small><sup>*</sup> Please note that the optimal antibody amount per ChIP should be determined by the end-user. We recommend testing 1-10 μl per IP.</small></p>',
'storage_conditions' => '',
'storage_buffer' => '',
'precautions' => 'This product is for research use only. Not for use in diagnostic or therapeutic procedures.',
'uniprot_acc' => '',
'slug' => '',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2022-02-24 14:04:47',
'created' => '0000-00-00 00:00:00',
'select_label' => '65 - AML1-ETO polyclonal antibody (A706-002 - not determined - Human - Whole antiserum - Rabbit)'
),
'Slave' => array(),
'Group' => array(
'Group' => array(
'id' => '276',
'name' => 'C15310197',
'product_id' => '2135',
'modified' => '2020-05-12 11:15:05',
'created' => '2020-05-12 11:15:05'
),
'Master' => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
),
'Product' => array(
(int) 0 => array(
[maximum depth reached]
)
)
),
'Related' => array(),
'Application' => array(
(int) 0 => array(
'id' => '19',
'position' => '10',
'parent_id' => '40',
'name' => 'WB',
'description' => '<p><strong>Western blot</strong> : The quality of antibodies used in this technique is crucial for correct and specific protein identification. Diagenode offers huge selection of highly sensitive and specific western blot-validated antibodies.</p>
<p>Learn more about: <a href="https://www.diagenode.com/applications/western-blot">Loading control, MW marker visualization</a><em>. <br /></em></p>
<p><em></em>Check our selection of antibodies validated in Western blot.</p>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'western-blot-antibodies',
'meta_keywords' => ' Western Blot Antibodies ,western blot protocol,Western Blotting Products,Polyclonal antibodies ,monoclonal antibodies ',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for western blot applications',
'meta_title' => ' Western Blot - Monoclonal antibody - Polyclonal antibody | Diagenode',
'modified' => '2016-04-26 12:44:51',
'created' => '2015-01-07 09:20:00',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '20',
'position' => '10',
'parent_id' => '40',
'name' => 'ELISA',
'description' => '<div class="row">
<div class="small-12 medium-12 large-12 columns">Enzyme-linked immunosorbent assay.</div>
</div>',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'elisa-antibodies',
'meta_keywords' => ' ELISA Antibodies,Monoclonal antibody, Polyclonal antibody',
'meta_description' => 'Diagenode offers Monoclonal & Polyclonal antibodies for ELISA applications',
'meta_title' => 'ELISA Antibodies - Monoclonal & Polyclonal antibody | Diagenode',
'modified' => '2016-01-13 12:21:41',
'created' => '2014-07-08 08:13:28',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '42',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-seq (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-seq-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP Sequencing applications',
'meta_title' => 'ChIP Sequencing Antibodies (ChIP-Seq) | Diagenode',
'modified' => '2016-01-20 11:06:19',
'created' => '2015-10-20 11:44:45',
'ProductsApplication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
[maximum depth reached]
)
)
),
'Category' => array(
(int) 0 => array(
'id' => '17',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-seq grade antibodies',
'description' => '<p><b>Unparalleled ChIP-Seq results with the most rigorously validated antibodies</b></p>
<p><span style="font-weight: 400;">Diagenode provides leading solutions for epigenetic research. Because ChIP-seq is a widely-used technique, we validate our antibodies in ChIP and ChIP-seq experiments (in addition to conventional methods like Western blot, Dot blot, ELISA, and immunofluorescence) to provide the highest quality antibody. We standardize our validation and production to guarantee high product quality without technical bias. Diagenode guarantees ChIP-seq grade antibody performance under our suggested conditions.</span></p>
<div class="row">
<div class="small-12 medium-9 large-9 columns">
<p><strong>ChIP-seq profile</strong> of active (H3K4me3 and H3K36me3) and inactive (H3K27me3) marks using Diagenode antibodies.</p>
<img src="https://www.diagenode.com/img/categories/antibodies/chip-seq-grade-antibodies.png" /></div>
<div class="small-12 medium-3 large-3 columns">
<p><small> ChIP was performed on sheared chromatin from 100,000 K562 cells using iDeal ChIP-seq kit for Histones (cat. No. C01010051) with 1 µg of the Diagenode antibodies against H3K27me3 (cat. No. C15410195) and H3K4me3 (cat. No. C15410003), and 0.5 µg of the antibody against H3K36me3 (cat. No. C15410192). The IP'd DNA was subsequently analysed on an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer's instructions. The 36 bp tags were aligned to the human genome using the ELAND algorithm. The figure shows the signal distribution along the complete sequence of human chromosome 3, a zoomin to a 10 Mb region and a further zoomin to a 1.5 Mb region. </small></p>
</div>
</div>
<p>Diagenode’s highly validated antibodies:</p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-seq-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-seq grade antibodies,polyclonal antibody,WB, ELISA, ChIP-seq (ab), ChIP-qPCR (ab)',
'meta_description' => 'Diagenode Offers Wide Range of Validated ChIP-Seq Grade Antibodies for Unparalleled ChIP-Seq Results',
'meta_title' => 'Chromatin Immunoprecipitation ChIP-Seq Grade Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:22',
'created' => '2015-02-16 02:24:01',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 1 => array(
'id' => '127',
'position' => '10',
'parent_id' => '4',
'name' => 'ChIP-grade antibodies',
'description' => '<div class="row">
<div class="small-12 columns"><center></center>
<p><br />Chromatin immunoprecipitation (<b>ChIP</b>) is a technique to study the associations of proteins with the specific genomic regions in intact cells. One of the most important steps of this protocol is the immunoprecipitation of targeted protein using the antibody specifically recognizing it. The quality of antibodies used in ChIP is essential for the success of the experiment. Diagenode offers extensively validated ChIP-grade antibodies, confirmed for their specificity, and high level of performance in ChIP. Each batch is validated, and batch-specific data are available on the website.</p>
<p></p>
</div>
</div>
<p><strong>ChIP results</strong> obtained with the antibody directed against H3K4me3 (Cat. No. <a href="../p/h3k4me3-polyclonal-antibody-premium-50-ug-50-ul">C15410003</a>). </p>
<div class="row">
<div class="small-12 medium-6 large-6 columns"><img src="https://www.diagenode.com/img/product/antibodies/C15410003-fig1-ChIP.jpg" alt="" width="400" height="315" /> </div>
<div class="small-12 medium-6 large-6 columns">
<p></p>
<p></p>
<p></p>
</div>
</div>
<p></p>
<p>Our aim at Diagenode is to offer the largest collection of highly specific <strong>ChIP-grade antibodies</strong>. We add new antibodies monthly. Find your ChIP-grade antibody in the list below and check more information about tested applications, extensive validation data, and product information.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'chip-grade-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'ChIP-grade antibodies, polyclonal antibody, monoclonal antibody, Diagenode',
'meta_description' => 'Diagenode Offers Extensively Validated ChIP-Grade Antibodies, Confirmed for their Specificity, and high level of Performance in Chromatin Immunoprecipitation ChIP',
'meta_title' => 'Chromatin immunoprecipitation ChIP-grade antibodies | Diagenode',
'modified' => '2024-11-19 17:27:07',
'created' => '2017-02-14 11:16:04',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 2 => array(
'id' => '102',
'position' => '1',
'parent_id' => '4',
'name' => 'Sample size antibodies',
'description' => '<h1><strong>Validated epigenetics antibodies</strong> – care for a sample?<br /> </h1>
<p>Diagenode has partnered with leading epigenetics experts and numerous epigenetics consortiums to bring to you a validated and comprehensive collection of epigenetic antibodies. As an expert in epigenetics, we are committed to offering highly-specific antibodies validated for ChIP/ChIP-seq and many other applications. All batch-specific validation data is available on our website.<br /><a href="../categories/antibodies">Read about our expertise in antibody production</a>.</p>
<ul>
<li><strong>Focused</strong> - Diagenode's selection of antibodies is exclusively dedicated for epigenetic research. <a title="See the full collection." href="../categories/all-antibodies">See the full collection.</a></li>
<li><strong>Strict quality standards</strong> with rigorous QC and validation</li>
<li><strong>Classified</strong> based on level of validation for flexibility of application</li>
</ul>
<p>Existing sample sizes are listed below. We will soon expand our collection. Are you looking for a sample size of another antibody? Just <a href="mailto:agnieszka.zelisko@diagenode.com?Subject=Sample%20Size%20Request" target="_top">Contact us</a>.</p>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => true,
'is_antibody' => true,
'slug' => 'sample-size-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => '5-hmC monoclonal antibody,CRISPR/Cas9 polyclonal antibody ,H3K36me3 polyclonal antibody,diagenode',
'meta_description' => 'Diagenode offers sample volume on selected antibodies for researchers to test, validate and provide confidence and flexibility in choosing from our wide range of antibodies ',
'meta_title' => 'Sample-size Antibodies | Diagenode',
'modified' => '2019-07-03 10:57:05',
'created' => '2015-10-27 12:13:34',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 3 => array(
'id' => '30',
'position' => '50',
'parent_id' => '4',
'name' => 'Transcription',
'description' => '<p><span style="font-weight: 400;">The list of Diagenode’s highly specific antibodies for transcription studies includes the antibodies against many transcription factors and nuclear receptors. Check the list below to see our targets.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li><span style="font-weight: 400;"> Highly sensitive and specific</span></li>
<li><span style="font-weight: 400;"> Cost-effective (requires less antibody per reaction)</span></li>
<li><span style="font-weight: 400;"> Batch-specific data is available on the website</span></li>
<li><span style="font-weight: 400;"> Expert technical support</span></li>
<li><span style="font-weight: 400;"> Sample sizes available</span></li>
<li><span style="font-weight: 400;"> 100% satisfaction guarantee</span></li>
</ul>',
'no_promo' => false,
'in_menu' => false,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'transcription-factor',
'cookies_tag_id' => null,
'meta_keywords' => ' Transcription factor antibodies,monoclonal antibodies,polyclonal antibodies',
'meta_description' => 'Diagenode offers polyclonal and monoclonal antibodies for Transcription studie',
'meta_title' => 'Transcription factor Antibodies | Diagenode',
'modified' => '2020-07-06 12:59:19',
'created' => '2015-03-12 10:20:08',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
),
(int) 4 => array(
'id' => '103',
'position' => '0',
'parent_id' => '4',
'name' => 'All antibodies',
'description' => '<p><span style="font-weight: 400;">All Diagenode’s antibodies are listed below. Please, use our Quick search field to find the antibody of interest by target name, application, purity.</span></p>
<p><span style="font-weight: 400;">Diagenode’s highly validated antibodies:</span></p>
<ul>
<li>Highly sensitive and specific</li>
<li>Cost-effective (requires less antibody per reaction)</li>
<li>Batch-specific data is available on the website</li>
<li>Expert technical support</li>
<li>Sample sizes available</li>
<li>100% satisfaction guarantee</li>
</ul>',
'no_promo' => false,
'in_menu' => true,
'online' => true,
'tabular' => false,
'hide' => true,
'all_format' => false,
'is_antibody' => true,
'slug' => 'all-antibodies',
'cookies_tag_id' => null,
'meta_keywords' => 'Antibodies,Premium Antibodies,Classic,Pioneer',
'meta_description' => 'Diagenode Offers Strict quality standards with Rigorous QC and validated Antibodies. Classified based on level of validation for flexibility of Application. Comprehensive selection of histone and non-histone Antibodies',
'meta_title' => 'Diagenode's selection of Antibodies is exclusively dedicated for Epigenetic Research | Diagenode',
'modified' => '2019-07-03 10:55:44',
'created' => '2015-11-02 14:49:22',
'ProductsCategory' => array(
[maximum depth reached]
),
'CookiesTag' => array([maximum depth reached])
)
),
'Document' => array(
(int) 0 => array(
'id' => '11',
'name' => 'Antibodies you can trust',
'description' => '<p style="text-align: justify;"><span>Epigenetic research tools have evolved over time from endpoint PCR to qPCR to the analyses of large sets of genome-wide sequencing data. ChIP sequencing (ChIP-seq) has now become the gold standard method for chromatin studies, given the accuracy and coverage scale of the approach over other methods. Successful ChIP-seq, however, requires a higher level of experimental accuracy and consistency in all steps of ChIP than ever before. Particularly crucial is the quality of ChIP antibodies. </span></p>',
'image_id' => null,
'type' => 'Poster',
'url' => 'files/posters/Antibodies_you_can_trust_Poster.pdf',
'slug' => 'antibodies-you-can-trust-poster',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2015-10-01 20:18:31',
'created' => '2015-07-03 16:05:15',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '38',
'name' => 'Epigenetic Antibodies Brochure',
'description' => '<p>More than in any other immuoprecipitation assays, quality antibodies are critical tools in many epigenetics experiments. Since 10 years, Diagenode has developed the most stringent quality production available on the market for antibodies exclusively focused on epigenetic uses. All our antibodies have been qualified to work in epigenetic applications.</p>',
'image_id' => null,
'type' => 'Brochure',
'url' => 'files/brochures/Epigenetic_Antibodies_Brochure.pdf',
'slug' => 'epigenetic-antibodies-brochure',
'meta_keywords' => '',
'meta_description' => '',
'modified' => '2016-06-15 11:24:06',
'created' => '2015-07-03 16:05:27',
'ProductsDocument' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
[maximum depth reached]
)
)
),
'Feature' => array(),
'Image' => array(
(int) 0 => array(
'id' => '1783',
'name' => 'product/antibodies/chipseq-grade-ab-icon.png',
'alt' => 'ChIP-seq Grade',
'modified' => '2020-11-27 07:04:40',
'created' => '2018-03-15 15:54:09',
'ProductsImage' => array(
[maximum depth reached]
)
)
),
'Promotion' => array(),
'Protocol' => array(),
'Publication' => array(
(int) 0 => array(
'id' => '3778',
'name' => 'RUNX1-ETO Depletion in t(8;21) AML Leads to C/EBPα- and AP-1-Mediated Alterations in Enhancer-Promoter Interaction.',
'authors' => 'Ptasinska A, Pickin A, Assi SA, Chin PS, Ames L, Avellino R, Gröschel S, Delwel R, Cockerill PN, Osborne CS, Bonifer C',
'description' => '<p>Acute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maintenance of t(8;21) AML is dependent on RUNX1-ETO expression. Its depletion causes extensive changes in transcription factor binding, as well as gene expression, and initiates myeloid differentiation. However, how these processes are connected within a gene regulatory network is unclear. To address this question, we performed Promoter-Capture Hi-C assays, with or without RUNX1-ETO depletion and assigned interacting cis-regulatory elements to their respective genes. To construct a RUNX1-ETO-dependent gene regulatory network maintaining AML, we integrated cis-regulatory element interactions with gene expression and transcription factor binding data. This analysis shows that RUNX1-ETO participates in cis-regulatory element interactions. However, differential interactions following RUNX1-ETO depletion are driven by alterations in the binding of RUNX1-ETO-regulated transcription factors.</p>',
'date' => '2019-09-17',
'pmid' => 'http://www.pubmed.gov/31533028',
'doi' => '10.1016/j.celrep.2019.08.040',
'modified' => '2019-10-02 16:57:08',
'created' => '2019-10-02 16:16:55',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '3130',
'name' => 'Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization',
'authors' => 'Schanda J. et al.',
'description' => '<p>RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nervy homology regions 1-4 (NHR1 to N HR4). The NHR domains serve as docking sites for a variety of different proteins and in addition the N HR2 domain mediates tetramerization through hydrophobic and ionic /polar interactions . Tetramerization is essential for RUNX1/ETO oncogenic activity. Destabilization of the RUNX1/ETO high molecular weight complex abrogates RUNX1/ETO oncogenic activity. Using a structure-based virtual screening, we identified several small molecule inhibitors mimicking the tetramerization hot spot within the NHR2 domain of RUNX1/ETO. One of these compounds, 7.44, was of particular interest as it showed biological activity in vitro and in vivo.</p>',
'date' => '2017-02-02',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/28154087',
'doi' => '',
'modified' => '2017-02-23 11:58:56',
'created' => '2017-02-23 11:50:26',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '3087',
'name' => 'The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs',
'authors' => 'Mandoli A. et al.',
'description' => '<p>The t(8;21) acute myeloid leukemia (AML)-associated oncoprotein AML1-ETO disrupts normal hematopoietic differentiation. Here, we have investigated its effects on the transcriptome and epigenome in t(8,21) patient cells. AML1-ETO binding was found at promoter regions of active genes with high levels of histone acetylation but also at distal elements characterized by low acetylation levels and binding of the hematopoietic transcription factors LYL1 and LMO2. In contrast, ERG, FLI1, TAL1, and RUNX1 bind at all AML1-ETO-occupied regulatory regions, including those of the AML1-ETO gene itself, suggesting their involvement in regulating AML1-ETO expression levels. While expression of AML1-ETO in myeloid differentiated induced pluripotent stem cells (iPSCs) induces leukemic characteristics, overexpression increases cell death. We find that expression of wild-type transcription factors RUNX1 and ERG in AML is required to prevent this oncogene overexpression. Together our results show that the interplay of the epigenome and transcription factors prevents apoptosis in t(8;21) AML cells.</p>',
'date' => '2016-11-15',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/27851970',
'doi' => '',
'modified' => '2017-01-02 11:07:24',
'created' => '2017-01-02 11:07:24',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2989',
'name' => 'MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML',
'authors' => 'Vegi NM et al.',
'description' => '<p>Homeobox genes are known to be key factors in leukemogenesis. Although the TALE family homeodomain factor Meis1 has been linked to malignancy, a role for MEIS2 is less clear. Here, we demonstrate that MEIS2 is expressed at high levels in patients with AML1-ETO-positive acute myeloid leukemia and that growth of AML1-ETO-positive leukemia depends on MEIS2 expression. In mice, MEIS2 collaborates with AML1-ETO to induce acute myeloid leukemia. MEIS2 binds strongly to the Runt domain of AML1-ETO, indicating a direct interaction between these transcription factors. High expression of MEIS2 impairs repressive DNA binding of AML1-ETO, inducing increased expression of genes such as the druggable proto-oncogene YES1. Collectively, these data describe a pivotal role for MEIS2 in AML1-ETO-induced leukemia.</p>',
'date' => '2016-07-12',
'pmid' => 'http://www.ncbi.nlm.nih.gov/pubmed/27346355',
'doi' => '10.1016/j.celrep.2016.05.094',
'modified' => '2016-07-29 09:46:05',
'created' => '2016-07-29 09:46:05',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2884',
'name' => 'Loss of TET2 in hematopoietic cells leads to DNA hypermethylation of active enhancers and induction of leukemogenesis',
'authors' => 'Rasmussen KD, Jia G, Johansen JV, Pedersen MT, Rapin N, Bagger FO, Porse BT, Bernard OA, Christensen J, Helin K',
'description' => '<p>DNA methylation is tightly regulated throughout mammalian development, and altered DNA methylation patterns are a general hallmark of cancer. The methylcytosine dioxygenase TET2 is frequently mutated in hematological disorders, including acute myeloid leukemia (AML), and has been suggested to protect CG dinucleotide (CpG) islands and promoters from aberrant DNA methylation. In this study, we present a novel <em>Tet2</em>-dependent leukemia mouse model that closely recapitulates gene expression profiles and hallmarks of human AML1-ETO-induced AML. Using this model, we show that the primary effect of <em>Tet2</em> loss in preleukemic hematopoietic cells is progressive and widespread DNA hypermethylation affecting up to 25% of active enhancer elements. In contrast, CpG island and promoter methylation does not change in a <em>Tet2</em>-dependent manner but increases relative to population doublings. We confirmed this specific enhancer hypermethylation phenotype in human AML patients with <em>TET2</em> mutations. Analysis of immediate gene expression changes reveals rapid deregulation of a large number of genes implicated in tumorigenesis, including many down-regulated tumor suppressor genes. Hence, we propose that TET2 prevents leukemic transformation by protecting enhancers from aberrant DNA methylation and that it is the combined silencing of several tumor suppressor genes in <em>TET2</em> mutated hematopoietic cells that contributes to increased stem cell proliferation and leukemogenesis.</p>',
'date' => '2015-04-17',
'pmid' => 'http://genesdev.cshlp.org/content/early/2015/04/15/gad.260174.115',
'doi' => '10.1101/gad.260174.115 ',
'modified' => '2016-04-07 09:39:29',
'created' => '2016-04-07 09:39:29',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '1847',
'name' => 'Immune evasion by oncogenic proteins of acute myeloid leukemia.',
'authors' => 'Elias S, Yamin R, Golomb L, Tsukerman P, Stanietsky-Kaynan N, Ben-Yehuda D, Mandelboim O',
'description' => 'PML-RARA and AML1-ETO are important oncogenic fusion proteins that play a central role in transformation to acute myeloid leukemia (AML). Whether these fusion proteins render the tumor cells with immune evasion properties is unknown. Here we show that both oncogenic proteins specifically downregulate the expression of CD48, a ligand of the natural killer (NK) cell activating receptor 2B4, thereby leading to decreased killing by NK cells. We demonstrate that this process is histone deacetylase (HDAC)-dependent, that it is mediated through the downregulation of CD48 messenger RNA, and that treatment with HDAC inhibitors (HDACi) restores the expression of CD48. Furthermore, by using chromatin immuoprecepitation (ChIP) experiments, we show that AML1-ETO directly interacts with CD48. Finally, we show that AML patients who are carrying these specific translocations have low expression of CD48.',
'date' => '2014-03-06',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/24449212',
'doi' => '',
'modified' => '2015-07-24 15:39:01',
'created' => '2015-07-24 15:39:01',
'ProductsPublication' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
[maximum depth reached]
)
)
),
'Testimonial' => array(),
'Area' => array(),
'SafetySheet' => array(
(int) 0 => array(
'id' => '2590',
'name' => 'AML1-ETO antibody SDS GB en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-GB-en-GHS_1_0.pdf',
'countries' => 'GB',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 1 => array(
'id' => '2592',
'name' => 'AML1-ETO antibody SDS US en',
'language' => 'en',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-US-en-GHS_1_0.pdf',
'countries' => 'US',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 2 => array(
'id' => '2587',
'name' => 'AML1-ETO antibody SDS DE de',
'language' => 'de',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-DE-de-GHS_1_0.pdf',
'countries' => 'DE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 3 => array(
'id' => '2591',
'name' => 'AML1-ETO antibody SDS JP ja',
'language' => 'ja',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-JP-ja-GHS_1_0.pdf',
'countries' => 'JP',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 4 => array(
'id' => '2586',
'name' => 'AML1-ETO antibody SDS BE nl',
'language' => 'nl',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-nl-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 5 => array(
'id' => '2585',
'name' => 'AML1-ETO antibody SDS BE fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-BE-fr-GHS_1_0.pdf',
'countries' => 'BE',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 6 => array(
'id' => '2589',
'name' => 'AML1-ETO antibody SDS FR fr',
'language' => 'fr',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-FR-fr-GHS_1_0.pdf',
'countries' => 'FR',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
),
(int) 7 => array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
[maximum depth reached]
)
)
)
)
$meta_canonical = 'https://www.diagenode.com/en/p/aml1-eto-polyclonal-antibody-classic-100-ul'
$country = 'US'
$countries_allowed = array(
(int) 0 => 'CA',
(int) 1 => 'US',
(int) 2 => 'IE',
(int) 3 => 'GB',
(int) 4 => 'DK',
(int) 5 => 'NO',
(int) 6 => 'SE',
(int) 7 => 'FI',
(int) 8 => 'NL',
(int) 9 => 'BE',
(int) 10 => 'LU',
(int) 11 => 'FR',
(int) 12 => 'DE',
(int) 13 => 'CH',
(int) 14 => 'AT',
(int) 15 => 'ES',
(int) 16 => 'IT',
(int) 17 => 'PT'
)
$outsource = true
$other_formats = array(
(int) 0 => array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
)
$pro = array(
'id' => '3068',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody (sample size)',
'description' => '',
'label1' => 'Validation data',
'info1' => '',
'label2' => '',
'info2' => '',
'label3' => '',
'info3' => '',
'format' => '20 µl',
'catalog_number' => 'C15310197-20',
'old_catalog_number' => '',
'sf_code' => 'C15310197-361',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '105',
'price_USD' => '115',
'price_GBP' => '100',
'price_JPY' => '16450',
'price_CNY' => '9500',
'price_AUD' => '288',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => false,
'last_datasheet_update' => '',
'slug' => 'aml1-eto-polyclonal-antibody-classic-20-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Antibody - ChIP-seq Grade (sample size)',
'modified' => '2022-01-05 14:49:04',
'created' => '2020-05-12 11:14:34',
'ProductsGroup' => array(
'id' => '313',
'product_id' => '3068',
'group_id' => '276'
)
)
$edit = ''
$testimonials = ''
$featured_testimonials = ''
$related_products = ''
$rrbs_service = array(
(int) 0 => (int) 1894,
(int) 1 => (int) 1895
)
$chipseq_service = array(
(int) 0 => (int) 2683,
(int) 1 => (int) 1835,
(int) 2 => (int) 1836,
(int) 3 => (int) 2684,
(int) 4 => (int) 1838,
(int) 5 => (int) 1839,
(int) 6 => (int) 1856
)
$labelize = object(Closure) {
}
$old_catalog_number = ''
$country_code = 'US'
$other_format = array(
'id' => '2135',
'antibody_id' => '65',
'name' => 'AML1-ETO Antibody',
'description' => '<p><span>Alternative name: <strong>RUNX1-RUNX1T1 <br /></strong></span></p>
<p><span>Polyclonal antibody raised in rabbit against the <strong>AML1-ETO</strong> fusion protein using a KLH-conjugated synthetic peptide.</span></p>',
'label1' => 'Validation Data',
'info1' => '<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIP.png" alt="AML1-ETO Antibody ChIP Grade" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 1. ChIP results obtained with the Diagenode antibody directed against AML1-ETO</strong><br />ChIP assays were performed using Kasumi-1 cells, the Diagenode antibody against AML1-ETO (Cat. No. C15310197) and optimized primer pairs for qPCR. Sheared chromatin from 1.25 million cells and 4 μl of antibody were used per ChIP experiment. QPCR was performed using primers specific for the FUT7, NFE2 and OGG1 genes. Figure 1 shows the occupancy, calculated as the ratio + control/background for which the promoter of the H2B gene was used.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p><small><strong>A.</strong>ChIP-seq signals on chromosome 3</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-A.png" alt="AML1-ETO Antibody ChIP-seq Grade" /><br /><small><strong>B.</strong>Genomic region on chromosome 3 surrounding the OGG1 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-B.png" alt="AML1-ETO Antibody for ChIP-seq" /><br /><small><strong>C. </strong>Genomic region on chromosome 9 surrounding the FUT7 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-C.png" alt="AML1-ETO Antibody for ChIP-seq assay" /><br /><small><strong>D. </strong>Genomic region on chromosome 12 surrounding the NFE2 gene</small><br /> <img src="https://www.diagenode.com/img/product/antibodies/C15310197_ChIPseq-D.png" alt="AML1-ETO Antibody validated in ChIP-seq" /></p>
<p></p>
</div>
<div class="small-6 columns">
<p><small><strong>Figure 2. ChIP-seq results obtained with the Diagenode antibody directed against AML1-ETO </strong><br />ChIP was performed as described above. The IP’d DNA of 6 ChIP’s was pooled and analysed with an Illumina Genome Analyzer. Library preparation, cluster generation and sequencing were performed according to the manufacturer’s instructions. The 32 bp tags were aligned to the human reference genome (hg18) using the ELAND algorithm. Figure 2 shows the results of the complete chromosome 3 and three genomic regions surrounding the OGG1, FUT7 and NFE2 genes, respectively. The position of the PCR amplicon is indicated with an arrow.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197-elisa.png" alt="AML1-ETO Antibody ELISA Validation" /></p>
<p class="text-center"></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 3. Determination of the antibody titer </strong><br />To determine the titer of the antibody, an ELISA was performed using a serial dilution of the Diagenode antibody directed against AML1-ETO (Cat. No. C15310197). The plates were coated with the peptides used for immunization of the rabbit. By plotting the absorbance against the antibody dilution (Figure 3), the titer of the antibody was estimated to be 1:32,750.</small></p>
</div>
</div>
<div class="row">
<div class="small-6 columns">
<p class="text-center"><img src="https://www.diagenode.com/img/product/antibodies/C15310197_WB.png" alt="AML1-ETO Antibody validated in Western Blot" /></p>
</div>
<div class="small-6 columns">
<p><small> <strong>Figure 4. Western blot analysis using the Diagenode antibody directed against AML1-ETO</strong><br />Nuclear extracts of SKNO-1 cells (15 μg) were analysed by Western blot using the Diagenode antibody against AML1-ETO (Cat. No. C15310197) diluted 1:1,000 in TBSTween containing 5% skimmed milk. The marker (in kDa) is shown on the left, the position of the protein of interest is indicated on the right.</small></p>
</div>
</div>',
'label2' => 'Target Description',
'info2' => '<p>This antibody specifically recognizes the AML1 (RUNX1) (UniProtKB/Swiss-Prot entry Q01196) - ETO (RUNX1T1) (UniProtKB/ Swiss-Prot entry Q06455) fusion protein that arises due to a translocation between chromosome 8 and 22 (t(8;21)(q22;q22)). This translocation is one of the most frequent karyotypic abnormalities observed in acute myeloid leukaemia. It produces a chimerical gene made up of the 5’-region of AML1and the 3’-region of ETO. The chimerical protein is thought to associate with the nuclear corepressor/histone deacetylase complex to block hematopoietic differentiation.</p>',
'label3' => '',
'info3' => '',
'format' => '100 µl',
'catalog_number' => 'C15310197',
'old_catalog_number' => '',
'sf_code' => 'C15310197-D001-001161',
'type' => 'FRE',
'search_order' => '03-Antibody',
'price_EUR' => '380',
'price_USD' => '380',
'price_GBP' => '340',
'price_JPY' => '59525',
'price_CNY' => '',
'price_AUD' => '950',
'country' => 'ALL',
'except_countries' => 'None',
'quote' => false,
'in_stock' => false,
'featured' => false,
'no_promo' => false,
'online' => true,
'master' => true,
'last_datasheet_update' => '0000-00-00',
'slug' => 'aml1-eto-polyclonal-antibody-classic-100-ul',
'meta_title' => 'AML1-ETO Antibody - ChIP-seq Grade (C15310197) | Diagenode',
'meta_keywords' => '',
'meta_description' => 'AML1-ETO Polyclonal Antibody validated in ChIP-seq, ChIP-qPCR, WB and ELISA. Batch-specific data available on the website. Other names: RUNX1-RUNX1T1 ',
'modified' => '2022-02-24 14:07:39',
'created' => '2015-06-29 14:08:20'
)
$img = 'banners/banner-cut_tag-chipmentation-500.jpg'
$label = '<img src="/img/banners/banner-customizer-back.png" alt=""/>'
$application = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'ProductsApplication' => array(
'id' => '5130',
'product_id' => '3068',
'application_id' => '43'
)
)
$slugs = array(
(int) 0 => 'chip-qpcr-antibodies'
)
$applications = array(
'id' => '43',
'position' => '10',
'parent_id' => '40',
'name' => 'ChIP-qPCR (ab)',
'description' => '',
'in_footer' => false,
'in_menu' => false,
'online' => true,
'tabular' => true,
'slug' => 'chip-qpcr-antibodies',
'meta_keywords' => 'Chromatin Immunoprecipitation Sequencing,ChIP-Seq,ChIP-seq grade antibodies,DNA purification,qPCR,Shearing of chromatin',
'meta_description' => 'Diagenode offers a wide range of antibodies and technical support for ChIP-qPCR applications',
'meta_title' => 'ChIP Quantitative PCR Antibodies (ChIP-qPCR) | Diagenode',
'modified' => '2016-01-20 11:30:24',
'created' => '2015-10-20 11:45:36',
'locale' => 'eng'
)
$description = ''
$name = 'ChIP-qPCR (ab)'
$document = array(
'id' => '292',
'name' => 'Datasheet AML1-ETO C15310197',
'description' => 'Datasheet description',
'image_id' => null,
'type' => 'Datasheet',
'url' => 'files/products/antibodies/Datasheet_AML1-ETO_C15310197.pdf',
'slug' => 'datasheet-aml1-eto-c15310197',
'meta_keywords' => null,
'meta_description' => null,
'modified' => '2015-07-07 11:47:43',
'created' => '2015-07-07 11:47:43',
'ProductsDocument' => array(
'id' => '2881',
'product_id' => '3068',
'document_id' => '292'
)
)
$sds = array(
'id' => '2588',
'name' => 'AML1-ETO antibody SDS ES es',
'language' => 'es',
'url' => 'files/SDS/AML1/SDS-C15310197-AML1-ETO_antibody-ES-es-GHS_1_0.pdf',
'countries' => 'ES',
'modified' => '2022-10-03 10:58:46',
'created' => '2022-10-03 10:58:46',
'ProductsSafetySheet' => array(
'id' => '4384',
'product_id' => '3068',
'safety_sheet_id' => '2588'
)
)
$publication = array(
'id' => '997',
'name' => 'ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.',
'authors' => 'Martens JH, Mandoli A, Simmer F, Wierenga BJ, Saeed S, Singh AA, Altucci L, Vellenga E, Stunnenberg HG',
'description' => '<p>ERG and FLI1 are closely related members of the ETS family of transcription factors and have been identified as essential factors for the function and maintenance of normal hematopoietic stem cells. Here, genome-wide analysis revealed that both ERG and FLI1 occupy similar genomic regions as AML1-ETO in t(8;21) AMLs and identified ERG/FLI1 as proteins that facilitate binding of oncofusion protein complexes. In addition, we demonstrate that ERG and FLI1 bind the RUNX1 promoter and that shRNA mediated silencing of ERG leads to reduced expression of RUNX1 and AML1-ETO, consistent with a role of ERG in transcriptional activation of these proteins. Finally, we identify H3 acetylation as the epigenetic mark preferentially associated with ETS factor binding. This intimate connection between ERG/FLI1 binding and H3 acetylation implies that one of the molecular strategies of oncofusion proteins such as AML1-ETO and PML-RARα involves the targeting of histone deacetylase activities to ERG/FLI1 bound hematopoietic regulatory sites. Together these results highlight the dual importance of ETS factors in t(8;21) leukemogenesis, both as transcriptional regulators of the oncofusion protein itself as well as proteins that facilitate AML1-ETO binding.</p>',
'date' => '2012-09-14',
'pmid' => 'https://www.ncbi.nlm.nih.gov/pubmed/22983443',
'doi' => '',
'modified' => '2016-05-03 12:14:08',
'created' => '2015-07-24 15:38:59',
'ProductsPublication' => array(
'id' => '4493',
'product_id' => '3068',
'publication_id' => '997'
)
)
$externalLink = ' <a href="https://www.ncbi.nlm.nih.gov/pubmed/22983443" target="_blank"><i class="fa fa-external-link"></i></a>'include - APP/View/Products/view.ctp, line 755
View::_evaluate() - CORE/Cake/View/View.php, line 971
View::_render() - CORE/Cake/View/View.php, line 933
View::render() - CORE/Cake/View/View.php, line 473
Controller::render() - CORE/Cake/Controller/Controller.php, line 963
ProductsController::slug() - APP/Controller/ProductsController.php, line 1052
ReflectionMethod::invokeArgs() - [internal], line ??
Controller::invokeAction() - CORE/Cake/Controller/Controller.php, line 491
Dispatcher::_invoke() - CORE/Cake/Routing/Dispatcher.php, line 193
Dispatcher::dispatch() - CORE/Cake/Routing/Dispatcher.php, line 167
[main] - APP/webroot/index.php, line 118
×
